PMCB Financials

Income Statement
MetricQ1 2027Q4 2026Q3 2026Q2 2026Q1 2026
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
1.0M
-82.9%
5.9M
+178.2%
2.1M
+53.9%
1.4M
+62.2%
848.3K
R&D
60.0K
-78.0%
273.1K
+193.3%
93.1K
-34.0%
141.1K
+48.3%
95.2K
SG&A
946.7K
-76.7%
4.1M
+101.0%
2.0M
+64.0%
1.2M
+64.0%
753.1K
Operating Income
-1006708
+82.9%
-5893461
-178.2%
-2118102
-53.9%
-1376051
-62.2%
-848305
EBITDA
-1006708
+76.8%
-4344034
-105.1%
-2118102
-53.9%
-1376051
-62.2%
-848305
Net Income
-5081191
+69.0%
-16379326
-2293.1%
746.9K
+110.1%
-7417975
+11.3%
-8360096
EPS (Basic)
$-0.54
+71.4%
$-1.89
-1011.8%
$-0.17
+86.3%
$-1.24
-0.8%
$-1.23
EPS (Diluted)
$-0.54
+71.4%
$-1.89
-1011.8%
$-0.17
+86.3%
$-1.24
-0.8%
$-1.23
Shares (Diluted)
10.7M
+0.7%
10.7M
+15.1%
9.3M
+36.3%
6.8M
+0.0%
6.8M
PharmaCyte Biotech (PMCB) โ€” Financials